EMA Authorised: Xromi (hydroxycarbamide) — Lipomed GmbH

View source ↗

Summary

The EMA authorised Xromi, a hydroxycarbamide medicine from Lipomed GmbH, for indications in anemia and sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Sickle Cell Disease

Drugs mentioned

• XROMI (HYDROXYUREA)

Snippet

Status: Authorised. Therapeutic area: Anemia, Sickle Cell. MAH: Lipomed GmbH. Decision date: 12/06/2025